Today: 11 June 2026
Lockheed Martin stock jumps near $500 to start 2026 as defense names catch a bid on contracts, geopolitics
4 January 2026
1 min read

Lockheed Martin stock jumps near $500 to start 2026 as defense names catch a bid on contracts, geopolitics

NEW YORK, Jan 4, 2026, 04:05 ET — Market closed.

  • Lockheed Martin ended Friday up 2.8% at $497.07, snapping a two-day slide.
  • Traders pointed to fresh Pentagon contract headlines and a broader lift across defense contractors.
  • Focus now shifts to late-January earnings, cash-flow assumptions and any new U.S. budget signals.

Lockheed Martin shares finished the first U.S. trading session of 2026 up 2.77% at $497.07 on Friday, outperforming a cluster of large aerospace and defense peers.

The move matters because Lockheed has started the year with investors still debating whether big primes can grow cash flow as the Pentagon leans harder on delivery performance, fixed-price programs and affordability.

Friday’s pop also pushed the stock back toward the psychologically important $500 level after a choppy finish to 2025, leaving it still below its 52-week high of about $516 set in October.

A key tailwind was renewed attention on contract activity tied to air and missile defense, including a Pentagon award with a ceiling value of $328.5 million for equipment described as meeting an “urgent operational need” for Taiwan’s air force. Reuters

Defense shares broadly rose on Friday as investors weighed geopolitics alongside procurement news, with Lockheed moving higher in step with other contractors.

In the group, RTX gained 2.10% and Northrop Grumman rose 2.71% on the day, while Boeing jumped 4.91%, MarketWatch data showed.

Not everyone on Wall Street is leaning in. JPMorgan analyst Seth Seifman downgraded Lockheed in late December, telling investors in a research note that pension-related outflows expected next year were likely to limit cash-flow growth relative to what many forecasts assume.

That cash-flow debate has been a recurring pressure point for the stock, since free cash flow is the pool that ultimately funds dividends and buybacks after capital spending.

Before next session, investors will watch whether the early-year bid holds as volumes normalize and as headlines around U.S. defense spending and overseas security risks continue to set the tone for the sector.

The next clear catalyst is earnings. Several market calendars currently peg Lockheed’s next report for late January, with estimates clustering around Jan. 27, though the company’s official investor calendar does not list an updated date.

Into that print, traders will be listening for updates on F-35 delivery cadence, missile-defense demand, and whether management reiterates expectations for 2026 cash generation amid pension and working-capital swings.

Stock Market Today

  • EMCOR Group (EME) Shares Show 33.7% Undervaluation Despite Strong Price Gains
    June 11, 2026, 10:55 AM EDT. EMCOR Group's (EME) stock closed at $776.72, up 21.6% year to date and 64.9% over the last year, but recent dips have raised valuation questions. Using a Discounted Cash Flow (DCF) analysis-a method that projects future cash flows discounted to present value-Simply Wall St estimates an intrinsic value of $1,171.22 per share. This suggests the stock is trading at a 33.7% discount, indicating undervaluation despite recent market pullbacks. The company benefits from strong exposure to U.S. construction and infrastructure projects, supporting its growth outlook. Investors should consider these factors alongside valuation metrics like price-to-earnings ratios when assessing EMCOR's attractiveness amidst sector dynamics.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
MARA stock jumps 10% as bitcoin miners rebound — what traders watch before Monday
Previous Story

MARA stock jumps 10% as bitcoin miners rebound — what traders watch before Monday

Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Next Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Go toTop